Manipulating Sp1 Activity to Improve Therapeutic Cloning

The observed over-expression of Sp1 target genes has inspired inventors to formulate a specific strategy for correcting many gene expression defects, and thus improve clone development. The invention is based on the belief that manipulating Sp1 activity can improve cloning. Inventors believe that cloning is inefficient in large part because of the continued expression of Sp1 target genes in the early cloned embryos, which causes clones to be very unlike normal embryos, and so makes them very unhealthy. Inventors propose that if over-expression of Sp1 target genes is prevented in early stage clones, this would greatly improve cloning efficiency by making the cloned embryos healthy again.

Patents:
US 20,090,138,979

Inventor(s): LATHAM KEITH [US]; VASSENA RITA [ES]; HAN ZHIMING [US]

Type of Offer: Licensing



Next Patent »
« More Biotech Patents
« More Pharmaceutical Patents

Share on      


CrowdSell Your Patent